April 2022 FDA Recall Gavilyte - C by Lupin Pharmaceuticals Inc.
D-0875-2022 - Failed Stability Specification

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on April 27, 2022 for the product Gavilyte - C. The FDA reported the reason for recall as failed stability specification. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0875-2022

Reason for Recall
Failed Stability Specification
Initiated
04-27-2022
Reported
05-25-2022
Quantity
26,910 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Product was distributed nationwide, including Puerto Rico.
GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19

Batch or Lot Expiration Information

Lot# S001132, exp. date July 2022 NDC # 43386-060-19

Affected Packages Involved in this Recall